Together with aberrantly active signal transduction pathways, a central role in MM pathogenesis is played by the chaperoning system of heat shock proteins (HSP) and by the ER stress/unfolded protein response (UPR), which are able to render MM cells resistant to pro-apoptotic stresses.
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Introduction
Significant progresses in understanding the pathogenesis of Multiple Myeloma (MM) -an incurable B-cell malignancy that originates from plasma cells (1) -prompted to test different molecules as therapeutic targets (2).
We described that protein kinase CK2 is crucial for MM cell survival, positively regulates STAT3 and NF-κB signalling and controls MM cell sensitivity to melphalan (3) . Indeed, CK2 critical role in maintaining the oncogenic phenotype suggests it could be an optimal therapeutic target (4). Phase 5 itself. PERK is a Ser/Thr protein kinase, which phosphorylates the translation regulator EIF2α, resulting in a reduction of mRNA translation and protein load in the ER. ATF6 translocates to the Golgi apparatus and is cleaved by proteases in an active form, which upregulates, among others, BIP/GRP78, PDI and EDEM1 transcription, resulting in increased ER chaperone activity and degradation of misfolded proteins. The transcription factor CHOP is induced downstream all the three UPR sensors (18, 19) . The critical importance of the UPR for normal and malignant plasma cells is highlighted by a number of studies (20, 21) . Recently, CK2 has been shown to control the ER stress response in prostate cancer cells (22) , however, whether the CK2/HSP90/CDC37 axis could take part in the UPR in plasma cells is presently unknown.
Here, we present data involving CK2 in UPR and suggesting that its inhibition could represent an effective therapeutic strategy to be exploited alone or in combination with ER stress/UPR pathways manipulation in MM. 
Results
CK2 partly localizes to the ER and its kinase activity is increased in MM cells upon ER stress.
The ER stress/UPR is an essential determinant of normal and malignant plasma cell fate (21, 28) . We asked whether CK2, as an essential molecule for MM cell survival (3), could be involved in the ER stress/UPR in MM cells.
Firstly, we checked whether CK2α (the catalytic subunit of this protein kinase) could localize to the ER in U-266, INA-6 cells and freshly isolated normal PBMC by confocal immunofluorescence microscopy. The Sarcoplasmic/ER Ca ++ -ATPase (SERCA) protein was used as an ER-specific control.
As shown in Fig. 1A , CK2α localized mainly in the cytoplasm, in both MM cell lines. SERCA staining was evident in discrete areas of the cell corresponding to the ER. A significant fraction of CK2α localized close to SERCA-rich areas (yellow fluorescence in the merge images) suggesting that a pool of this kinase lies in the ER. In normal PBMC we observed a similar pattern of CK2α staining and, even if at a lesser extent than in MM cells, an evident CK2α-SERCA colocalization.
Next, we investigated whether CK2 activity could be influenced by ER stress. To this aim, we treated U-266 and H-929 MM cells (not shown) with the ER stress inducer thapsigargin (TG). As shown in Fig. 1B , TG caused an increase of CK2 kinase activity against a synthetic peptide (see Methods for details) in a time-dependent manner (p=0.014 for the 6h and p=0.020 for the 24h time point). Moreover (top right panel), TG caused increased Ser 13 CDC37 phosphorylation, which is a well-known CK2 substrate (12) . We also checked whether ER stress could change CK2 intracellular localization assuming that this kinase could concentrate in the ER. However, WB analysis of CK2α in the microsomal (marked by high rS6 kinase expression) and cytosolic (with high GAPDH levels) cellular subfractions did not show significant changes of CK2 distribution upon ER stress induction (Fig 1B, bottom right panel) . These observations indicate that ER stress induces 9 CK2 activity without modifying its ER-specific localization.
CK2 inactivation in MM cells affects the ER stress/UPR signaling cascades. We next investigated
whether inhibition of CK2 activity could affect the main ER stress-induced UPR signaling cascades.
To this aim, we treated U-266 MM cells with the selective, ATP-competitive CK2 chemical inhibitor K27 for 18 hours. We employed the inhibitor at different concentrations, according to our previously published dose-response tests (3). K27 is a 4,5,6,7-tetrabromobenzimidazole (TBB) derivative (29) displaying a fairly good specificity for CK2 at the concentration here used. However, as shown in (29) , at higher concentrations (10 μM and higher) it is possible that K27 has off target effects towards other kinases. Interestingly, WB analysis of control and K27-treated U-266 cells revealed significant modifications of the main UPR regulating signaling molecules upon K27: a strong reduction of IRE1α, a reduction of BIP/GRP78 and CHOP/GADD153 protein levels and an increase of phospho-Ser 51 EIF2α levels (Fig. 1C) . To validate these findings, we performed RNA interference experiments to down regulate CK2α levels in U-266 cells. As shown in Fig. 1D , WB analysis confirmed that CK2α was efficiently knocked down upon nucleofection of U-266 cells with specific siRNAs (the densitometric analysis showed about a 50% protein level reduction (graph at the bottom); densitometry value=0.53 ± SEM 0.03 over the control, p<0.05, n=12). CK2α-knocked-down MM cells displayed alterations of the UPR-related proteins similar to those observed in the conditions of CK2 chemical inhibition. We therefore checked the EIF2α upstream kinase PERK, and, remarkably, we could detect that CK2α-silencing caused increased phosphorylation of PERK at Thr 981. However, in CK2α-silenced samples we could not detect a significant reduction of CHOP/GADD153 protein levels. Finally, the levels of IRE1α phosphorylated on Ser 724 -which are dependent on IRE1α kinase activity itself -did not change upon CK2 inhibition either with K27 or RNA interference and were barely detectable under these conditions 
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( Fig. S1A, B) . Of note, both K27 and CK2α knockdown with siRNAs were accompanied by PARP cleavage, confirming the essential role of CK2 for MM cell survival.
Next, we checked the transcriptional program set up by the ER stress/UPR pathways upon CK2α silencing. To this aim, we performed quantitative PCR analysis of mRNA expression of direct UPR target genes, namely BIP/GRP78, EDEM and CHOP/GADD153 on cDNA extracted from U-266 cells nucleofected with control or CK2α-directed siRNA oligos. As shown in Fig. 1E , CK2α mRNA levels were significantly reduced in these experiments. We observed a significant reduction of expression for BIP/GRP78 and an increase for EDEM in the CK2α-silenced samples (p<0.05, n=4), while there was no statistically sizeable difference for CHOP/GADD153 (although a trend towards reduced levels could be appreciated). We also determined the amount of XBP1s (spliced) over XBP1u (unspliced), which measures IRE1α-dependent endoribonuclease activity under ER stress conditions. XBP1 is a transcription factor essential for plasma cell development (28) and whose overexpression is associated with myelomagenesis (21) . In agarose gel, the XPB1s band was appreciated upon TG stimulation, however, it was undetectable under CK2α RNA interference (Fig.   1F , upper panel); nonetheless, a more sensitive quantification of the relative amounts of XBP1s/XBP1u -through the gene scan fragment length analysis technique -showed that XBP1s over XBP1u is significantly reduced under inhibition of CK2α by RNA interference, as compared with scramble nucleofected controls (Fig. 1F, bottom panel, p<0 .05, n=6).
CK2 protects from TG-induced MM cell apoptosis and mediates the activation of UPR pathways.
We next asked whether ER-stress-induced MM cell apoptosis could be influenced by CK2 inactivation. First, we looked at survival of normal B lymphocytes and MM cells by annexin V staining upon TG, K27 or TG plus K27 treatment for 6 and 18 hours. As shown in Fig. 2A, both TG and K27 were able to induce a significant amount of apoptosis of U-266 cells after 6 hours. TG-induced apoptosis was stronger at 18 hours (data not shown). Remarkably, the treatment with the two molecules in combination caused a statistically significant higher level of apoptosis -as compared to the single treatments (p<0.05, n=4) -only in malignant plasma cells (Fig. 2B ). This effect lasted up to 18 hours (data not shown). Furthermore, RNA interference experiments confirmed that also CK2α silencing -coupled with TG treatment -led to a significantly higher rate of cell death than the single conditions (Fig. 2C, p<0.05, n=4) . Lastly, the cooperation between CK2 inhibition and TG treatment was evident even on INA-6 MM cells (CD45+) grown in the protective presence of HS-5 bone marrow stromal cells (CD45-), a model, which reproduces some features of the MM milieu (see Materials and Methods) (Fig. 2D, p<0 .05, n=4). Here, K27 was used at a lower concentration (2 μM), due to the higher sensitivity of INA-6 cells to CK2 inhibitors that we observed in dose-response assays (not shown). WB analysis on U-266 MM cells treated with TG and K27 for 6 and 18 hours (Fig. 2E, F) showed that TG induced an increase of IRE1α, CHOP/GADD153 and BIP/GRP78 levels oppositely than CK2 inhibition with K27, which led to a reduction of the three proteins (more evident at 18 hours). TG and K27 caused an increase of phospho-Thr 981 PERK. Remarkably, in the combined treatment with TG plus K27, TG-induced increase of IRE1α, BIP/GRP78 and CHOP/GADD153 was attenuated or even abolished by K27, while the elevation of phospho-Thr 981 PERK remained unaffected. We also carried out RNA interference experiments and TG treatment. CK2α silencing alone showed similar changes to those observed with K27. In the combined treatment, we observed an analogous pattern of changes, even though to a lesser extent as compared to K27 (Fig. 2G) . Altogether, these data suggest that CK2 protects from ER stress-induced apoptosis and sustains a specific UPR by upregulating IRE1α level and downregulating PERK activity in MM cells.
Research. and Methods) and found that the combination index was 0.291, indicating a strong synergism between K27 and GA (Fig. 3A ). Next, we tested whether apoptosis could be involved in this inhibitors caused a much higher rate of apoptosis than the single inhibition of the two molecules (p<0.05, n=4), in all the conditions. WB analysis of cleaved PARP protein levels validated all these results ( Fig. S2A ). Lastly, we assayed whether the synergy of CK2/HSP90 inhibitors was present also on primary malignant plasma cells from patients. To this aim, CD138+ plasma cells from eight MM patients (see Table 1 for clinical details) were treated with GA (0.15 μM), K27 (2 μM) or the combination of the two for 18 hours. Fig. 3H summarizes the data obtained. Each compound determined apoptosis, which was significantly greater upon combination of both drugs (p<0.05, n=8). We also carried out RNA interference experiments. Control or CK2α-silenced U-266 cells were exposed to HSP90 inhibition with GA (0.15 or 0.5 μM) for 6 hours. Exposure to GA of CK2α-silenced MM cells led to higher cytotoxicity than the single HSP90 inhibition or CK2α silencing ( 
In vivo anti-myeloma effects of CK2 inhibition
To solidify our results obtained with MM cells lines and cells from MM patients, we set up an in vivo mouse xenograft MM model by subcutaneous injection of U-266 cells in CB17-SCID mice.
Mice were randomized to receive the vehicle, the CK2 inhibitor tTBB (which is structurally closely
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on April 14, 2017. © 2012 American Association for Cancer clincancerres.aacrjournals.org Downloaded from 14 related to K27 of which it is the precursor) (26) , and tTBB plus the HSP90 inhibitor 17-AAG. Tumor volume was measured every day up to 32 days. As shown in Fig. S3 , tTBB caused a marked reduction of tumor growth as compared with the vehicle-receiving control group (p<0.05 at day 32). Remarkably, the combined treatment with tTBB and 17-AAG appeared to provide higher antigrowth efficacy as compared to tTBB alone (p<0.05 at day 32). Overall, these data suggest that in vivo CK2 inhibition is able to cause a strong MM cell growth arrest, which is potentiated by the simultaneous inhibition of HSP90.
CK2 regulates the HSP90-dependent UPR in MM cells. Our data suggest that CK2 could regulate the UPR pathways through, at least, two means, i.e. stabilization of IRE1α protein and inhibition of PERK. As these are two HSP90-modulated processes (30), we checked the effects of CK2 and HSP90 inhibition on the ER stress/UPR cascades in MM cells.
To this aim, we looked at the expression of UPR proteins by WB at different time lapses (3 and 6 hours) upon CK2, HSP90 or both proteins inhibition. Treatment of U-266 and RPMI-8226 cells with GA caused a reduction of IRE1α protein levels, which began as early as after 3 hours (Fig. S4A, B) and was more evident after 6 hours ( Figure 4A, B) . Only in RPMI-8266, GA 0.5 μM caused a rise of BIP/GRP78 levels after 6 hours. In both cell lines GA caused a reduction of phospho-Ser 51 EIF2α and, in U-266 cells, also of total and phospho-Thr 981 PERK levels. These data are in line with previously published work (15) . Remarkably, K27 markedly enhanced the GA-dependent reduction of IRE1α and caused a decrease of BIP/GRP78 at 6 hours, which was clear especially in RPMI-8226 cells and in U-266 cells at later time points (18 hours , Fig. 1C ). K27 to some extent opposed the GA-driven BIP/GRP78 rise (more evident at the mRNA level, as shown below). Moreover, in cells treated with the combination of the two agents, the K27-dependent increase of phospho-Ser 51 EIF2α was minimally affected by the addition of GA, as was the increase of phospho-Thr 981 PERK. Importantly, these changes of BIP/GRP78 and phospho-Ser 51 EIF2α were also clearly seen in freshly isolated plasma cells from MM patients treated with GA, K27 or both agents (Fig. 4C) .
Experiments of RNA interference down regulating CK2α and treatment with GA for 3 (Fig. S4, C) and 6 hours (Fig. 4D) in part reproduced the effects obtained with K27 on IRE1α and BIP/GRP78.
Similarly, CK2α silencing slightly antagonized GA-induced reduction of phospho-Ser 51 EIF2α, total and phospho-Thr 981 PERK. Lastly, we analyzed the IRE1α-triggered XBP1s mRNA formation upon treatment of MM cells with GA, K27 or both. As shown in Fig. 4E , GA treatment led to XBP1s production only at very early time points (1 hour). At later time points (3 and 6 hours), in GAtreated samples, XBP1s disappeared, possibly due to IRE1α degradation and inactivation. CK2 inhibition with K27 seemed not to affect XBP1 splicing at any time point and, when used with GA, did not result in changes of the GA-induced effects at 1 hour, in agarose gel. However, similarly as for the data shown in Fig. 1F , assessment of XBP1s levels with the gene scan fragment length analysis revealed that K27 indeed caused a reduction of XBP1s (data not shown).
Transcription of UPR genes upon HSP90 inhibition is regulated by CK2. Next, we examined the consequences of CK2 inactivation on the GA-induced transcription of UPR-dependent genes, namely BIP/GRP78, EDEM and CHOP/GADD153 by quantitative real-time PCR. In a set of experiments, we treated U-266 cells with GA at increasing concentrations (0.15 μM and 0.5 μM), K27 (5 μM) or both. As shown in Fig. 5A , GA caused a dose-dependent increase of all the three target genes examined at 3 and 6 hours. K27 did not affect BIP/GRP78 mRNA levels at these early time points (but it did reduce the protein at later time points, Fig. 1C ), however it triggered EDEM and, most noticeably, inhibited CHOP/GADD153 transcription (p<0.05, n=3). Noteworthy, in the combination experiments, K27 strongly hampered the GA-induced rise of the target genes (p<0.05, n=3). In another set of experiments, CK2α was targeted by RNA interference and U-266
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cells were exposed to GA for 3 and 6 hours (Fig. 5B) . CK2α mRNA levels were reduced by 70-80% (data not shown). CK2α silencing led to a slight but significant reduction of BIP/GRP78 and a more significant increase of EDEM mRNA. Remarkably, the GA-induced up regulation of BIP/GRP78 mRNA expression was inhibited by CK2α knockdown. CHOP/GADD153 mRNA was unaffected by CK2α knockdown; however, CK2α silencing effectively opposed its rise triggered by GA at 3 hours (p<0.05).
Altogether, these data show that CK2α is needed for the HSP90-dependent IRE1α-mediated UPR in MM cells.
CK2 inhibition causes a reduction of HSP90/CDC37/IRE1α complexes in MM cells
CK2 controls the HSP90-dependent folding of client protein kinases through phosphorylation of 
Discussion
We show here that protein kinase CK2 is activated by ER-stress, lies upstream from IRE1α and PERK signalling branches, protects from ER-stress triggered apoptosis and synergizes with HSP90 inhibition in inducing MM cell growth arrest. Mechanistically, CK2 might control HSP90-dependent IRE1α protein stability and the extent of EIF2α phosphorylation.
CK2α localizes close to the ER (Fig. 1A) . This finding in MM cells extended previous reports in other cell types showing that CK2 localizes to the ER and phosphorylates ER-resident proteins (31) (32) (33) .
ER stress with TG increased CK2-specific activity (Fig. 1B) . This observation is, to our knowledge, the first ever reported. Ablation of CK2 function resulted in a decrease of IRE1α and of BIP/GRP78
and in an increase of phospho-Thr 981 PERK and phopsho-Ser 51 EIF2α protein levels (Fig. 1C, D) .
This suggests that CK2 might inhibit PERK-mediated EIF2α phosphorylation at basal conditions. CK2 silencing led to a repression of BIP/GRP78 and a stimulation of EDEM mRNA expression (Fig.   1E ). BIP/GRP78 and EDEM mRNA are up-regulated following ER stress by the action of the IRE1α and ATF6 branches of the UPR, respectively (reviewed in (34)). Therefore, the reduction of IRE1α levels and of XBP1s upon CK2 inhibition could justify the decrease of the XBP1 target BIP/GRP78; on the other hand, the observed increase of the ATF6 target gene EDEM upon CK2 inhibition suggests that CK2 could restrain the ATF6-dependent signalling. Therefore, CK2 might regulate the UPR by maintaining IRE1α levels and buffering down PERK and ATF6 activity in MM cells.
Importantly, this type of homeostatic UPR has been associated to a compensatory, protective mechanism peculiar of plasma cells, in which by keeping the PERK-mediated axis buffered down and the IRE1α/XBP1-dependent defensive response up regulated, protein synthesis and antibodies production are ensured (35) . Under stressed conditions, CK2 inhibition potentiated TGinduced MM cell apoptosis (Fig. 2) . The increase of CK2 activity, IRE1α, BIP/GRP78, CHOP/GADD153 and phospho-Thr 981 PERK protein levels, observed upon TG treatment, could (Fig. 3 and Fig. S3 ). Remarkably, to our knowledge, the experiments with the mouse model are the first description of an in vivo anti-myeloma activity of CK2 inhibitors ever reported.
Moreover, we provided original evidence that CK2 and HSP90 cooperate in maintaining IRE1α levels and activity, whereas they act in opposite ways on the PERK-dependent axis (Fig. 4) . CK2 inactivation impaired the GA-induced expression of IRE1α-XBP1 targets, such as BIP/GRP78, triggered the transcription of the ATF6 target gene EDEM and buffered down that of CHOP/GADD153 (Fig. 5) . Our data for the first time implicate CK2 in the transcription of ER stress/UPR-driven genes. The outcome of CK2 inhibition on CHOP/GADD153 levels deserves further investigation. CHOP/GADD153 mRNA is up-regulated by the IRE1α-XBP1, EIF2α-ATF4 and ATF6 branches (34) . According to our results, these latter two cascades could be activated upon CK2 inhibition; therefore CHOP/GADD153 mRNA levels would be expected to increase. On the other hand, the strong impairment of IRE1α-XBP1, and perhaps of other transcription factors that stimulates CHOP/GADD153 expression, could account for the CHOP/GADD153 mRNA decrease that we instead observed. However, reports have suggested a secondary role for CHOP in normal and malignant plasma cell survival (36, 37) . It must be noted that the different effects obtained using K27 or CK2 silencing could be due, at least in part, to the different degree of CK2α protein activity reduction using the two approaches.
Mechanistically, CK2 inhibition resulted in a reduction of HSP90, CDC37 and IRE1α complexes in the cell, thus likely leading to accelerate IRE1α turnover (Fig. 6A) . CK2 is known to associate with HSP90 and this interaction establishes a mutual regulation (38, 39) .
Notably, the very recent finding that IRE1α could represent a therapeutic target for MM provides a strong support for the importance of this signalling system in this blood tumor (40). 
